Nov 09,2020

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer 2020 Annual Meeting

Incyte (Nasdaq:INCY) today announced that abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, held virtually from November 11-14, 2020.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 09,2020

OncoHost to Present Data on Predicting Host Response to Immunotherapy in Melanoma Patients at SITC 2020

OncoHost, a global leader in host response profiling for improved personalized cancer therapy, announced today that its abstract on the use of plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients was accepted for the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting. The presentation will take place on November 14 at 12:25 PM EST. The clinical study was conducted in collaboration with the University of Connecticut, Yale University's Cancer Center and the Technion Institute of Technology.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 15,2020

OncoHost Offers New Hope For Cancer Sufferers

Israel’s OncoHost is developing a new ways to test the blood of cancer patients in order to determine which treatments will be the most effective. OncoHost offers what it describes as personalized strategies to maximize the success of cancer therapy. It has a proprietary proteomic analysis which the company says can be used to understand an individual patient’s unique response to therapy in order to overcome one of the major obstacles in clinical oncology today – resistance to therapy.

View Analyst & Ambassador Comments
Go to original news
Nov 16,2020

Voluntis receives CE Mark for Oleena, key milestone to the future commercialization of its digital therapeutic for oncology

Voluntis (Euronext Paris, Ticker: VTX – ISIN: FR0004183960), a leader in digital therapeutics, today announced that it has received the CE mark for Oleena. This is a key first step ahead of the commercialization of its oncology solutions in the European Union.

REGULATORY CE MARK

#dtx

#rpm

#platform

View Analyst & Ambassador Comments
Go to original news
Nov 18,2020

Launch of a new R&D program to extend the Theraxium platform supported by a loan from BPIFrance

Voluntis (Euronext Paris, Ticker: VTX – ISIN: FR0004183960) a leader in digital therapeutics, today announced the launch of a new R&D program to advance the capabilities of its Theraxium platform. It also announced a new loan obtained from Bpifrance to support its innovation program. This €1 million loan has a term of six years and two months. This term includes a deferred principal repayment period of 14 months followed by a straight-line repayment period over 5 years. The first installment will be payable on March 31, 2022 and the last installment payable on December 31, 2026.

PRODUCT

#ai/software

#platform

#rwd

View Analyst & Ambassador Comments
Go to original news
Nov 24,2020

Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event

Novartis is hosting today its annual Meet Novartis Management event giving investors and industry analysts the opportunity to meet with key executives across the company. The virtual meeting provides a deeper view into the company's progress on its ongoing transformation and growth strategy focused on becoming the leading medicines company powered by data science and advanced therapy platforms.

View Analyst & Ambassador Comments
Go to original news
Dec 17,2020

Kaiku Health has taken its first steps to predict treatment response of cancer patients for immune checkpoint inhibitor therapies with machine learning

Kaiku Health has taken its first steps to tackle the big issue related to the challenge of identifying which patients are likely to benefit from immune checkpoint inhibitor (ICI) therapies. In collaboration with Oulu University Hospital (OYS), Kaiku Health conducted a study which investigated whether machine learning (ML) could be used to predict the treatment response, or more specifically objective response rate (ORR) of ICI treated patients, based on clinical and patient-reported data. ORR was defined as the proportion of patients in whom partial (PR) or complete (CR) responses were seen as the best overall response. The results of this study were presented at the ESMO IO 2020 Virtual Congress last week and received remarkable attention from the European Society for Medical Oncology.

CLINICAL STUDY

#ml

View Analyst & Ambassador Comments
Go to original news
Dec 07,2020

Predicting patient-reported symptoms for cancer patients undergoing immune checkpoint inhibitor (ICI) therapies using different measurement system than in prediction model training

Kaiku has continued its work among building machine learning (ML) based prediction models for immunotherapy-related symptom development. A year ago results from the first study were presented in the ESMO IO congress 2019 where it was showcased that ML based modeling of ePRO data on ICI treated cancer patients is feasible in predicting the onset and continuation of symptoms related to ICI toxicities. Now, in a study conducted together with Dr.med Razvan Popescu & Tumor Zentrum Aarau from Switzerland it was proven that the previously built models generalize well to data collected using different symptom measurement system (PRO-CTCAE) in a different geographical area. The results are promising and Kaiku and Tumor Zentrum Aarau plan to continue the joint research.

CLINICAL STUDY

#ml

View Analyst & Ambassador Comments
Go to original news
Dec 17,2020

Carevive Selected by Methodist Le Bonheur Healthcare

Methodist Le Bonheur Healthcare System will implement Carevive’s comprehensive oncology continuum of care solution integrated with their Electronic Health Record (EHR), giving clinicians access to vital oncology patient information at the point of care. The Carevive decision was made in September and kicked off in mid-October with an expected go-live early 2021.

COLLABORATION PARTNERSHIP

#institution

#rpm

View Analyst & Ambassador Comments
Go to original news
Dec 08,2020

Kaiku Health to present research at ESMO Immuno-Oncology Congress 2020

Kaiku Health, together with Oulu University Hospital, will present research at the ESMO Immuno-Oncology Congress 2020, which takes place as a virtual conference this year. The research investigates the use of Machine Learning to predict the objective response rate in immune checkpoint inhibitor treated patients when patient-reported and clinical data data are used as input for the Machine Learning based model.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY